S&P 500   3,110.63 (-0.07%)
DOW   27,619.14 (-0.11%)
QQQ   202.25 (-0.09%)
AAPL   264.45 (+1.04%)
MSFT   149.78 (-0.05%)
GOOGL   1,318.50 (-0.03%)
AMZN   1,743.56 (-0.97%)
CGC   18.62 (+1.31%)
NVDA   208.49 (-0.44%)
MU   46.42 (+0.26%)
BABA   199.89 (+3.17%)
GE   10.82 (-0.83%)
TSLA   330.74 (-0.69%)
T   38.30 (+0.52%)
AMD   39.72 (+0.08%)
PRI   134.32 (+0.84%)
NFLX   299.63 (-1.54%)
BAC   33.10 (-0.15%)
GILD   65.85 (-1.35%)
DIS   148.01 (-0.18%)
S&P 500   3,110.63 (-0.07%)
DOW   27,619.14 (-0.11%)
QQQ   202.25 (-0.09%)
AAPL   264.45 (+1.04%)
MSFT   149.78 (-0.05%)
GOOGL   1,318.50 (-0.03%)
AMZN   1,743.56 (-0.97%)
CGC   18.62 (+1.31%)
NVDA   208.49 (-0.44%)
MU   46.42 (+0.26%)
BABA   199.89 (+3.17%)
GE   10.82 (-0.83%)
TSLA   330.74 (-0.69%)
T   38.30 (+0.52%)
AMD   39.72 (+0.08%)
PRI   134.32 (+0.84%)
NFLX   299.63 (-1.54%)
BAC   33.10 (-0.15%)
GILD   65.85 (-1.35%)
DIS   148.01 (-0.18%)
S&P 500   3,110.63 (-0.07%)
DOW   27,619.14 (-0.11%)
QQQ   202.25 (-0.09%)
AAPL   264.45 (+1.04%)
MSFT   149.78 (-0.05%)
GOOGL   1,318.50 (-0.03%)
AMZN   1,743.56 (-0.97%)
CGC   18.62 (+1.31%)
NVDA   208.49 (-0.44%)
MU   46.42 (+0.26%)
BABA   199.89 (+3.17%)
GE   10.82 (-0.83%)
TSLA   330.74 (-0.69%)
T   38.30 (+0.52%)
AMD   39.72 (+0.08%)
PRI   134.32 (+0.84%)
NFLX   299.63 (-1.54%)
BAC   33.10 (-0.15%)
GILD   65.85 (-1.35%)
DIS   148.01 (-0.18%)
S&P 500   3,110.63 (-0.07%)
DOW   27,619.14 (-0.11%)
QQQ   202.25 (-0.09%)
AAPL   264.45 (+1.04%)
MSFT   149.78 (-0.05%)
GOOGL   1,318.50 (-0.03%)
AMZN   1,743.56 (-0.97%)
CGC   18.62 (+1.31%)
NVDA   208.49 (-0.44%)
MU   46.42 (+0.26%)
BABA   199.89 (+3.17%)
GE   10.82 (-0.83%)
TSLA   330.74 (-0.69%)
T   38.30 (+0.52%)
AMD   39.72 (+0.08%)
PRI   134.32 (+0.84%)
NFLX   299.63 (-1.54%)
BAC   33.10 (-0.15%)
GILD   65.85 (-1.35%)
DIS   148.01 (-0.18%)
Log in

LON:STX - Shield Therapeutics Share Price, Forecast & News

GBX 189
-0.50 (-0.26 %)
(As of 12/5/2019 01:30 PM ET)
Today's Range
189
Now: GBX 189
190.65
50-Day Range
181.50
MA: GBX 184.23
193
52-Week Range
30
Now: GBX 189
202
Volume78,035 shs
Average Volume48,665 shs
Market Capitalization£221.49 million
P/E Ratio52.50
Dividend YieldN/A
BetaN/A
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-191-5118500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£14.00 million
Cash FlowGBX 5.66 per share
Book ValueGBX 33.10 per share

Profitability

Miscellaneous

Employees15
Market Cap£221.49 million
Next Earnings DateN/A
OptionableOptionable

Receive STX News and Ratings via Email

Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.


Shield Therapeutics (LON:STX) Frequently Asked Questions

What is Shield Therapeutics' stock symbol?

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

What price target have analysts set for STX?

3 analysts have issued 1 year price targets for Shield Therapeutics' shares. Their forecasts range from GBX 116 to GBX 200. On average, they anticipate Shield Therapeutics' stock price to reach GBX 179 in the next year. This suggests that the stock has a possible downside of 5.3%. View Analyst Price Targets for Shield Therapeutics.

What is the consensus analysts' recommendation for Shield Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics.

Has Shield Therapeutics been receiving favorable news coverage?

Media coverage about STX stock has been trending somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Shield Therapeutics earned a news impact score of 0.9 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Shield Therapeutics.

Who are some of Shield Therapeutics' key competitors?

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and Skinbiotherapeutics (SBTX).

Who are Shield Therapeutics' key executives?

Shield Therapeutics' management team includes the folowing people:
  • Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)
  • Mr. Timothy William Watts, Chief Financial Officer (Age 61)
  • Fleur Wood, Director of Investor Relations
  • Ms. Lucy Bailey, Gen. Counsel & Company Sec.
  • Ms. Suzanne Wood, Group HR Director

How do I buy shares of Shield Therapeutics?

Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shield Therapeutics' stock price today?

One share of STX stock can currently be purchased for approximately GBX 189.

How big of a company is Shield Therapeutics?

Shield Therapeutics has a market capitalization of £221.49 million and generates £14.00 million in revenue each year. Shield Therapeutics employs 15 workers across the globe.View Additional Information About Shield Therapeutics.

What is Shield Therapeutics' official website?

The official website for Shield Therapeutics is http://www.shieldtherapeutics.com/.

How can I contact Shield Therapeutics?

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.


MarketBeat Community Rating for Shield Therapeutics (LON STX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  323
MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel